STOCK TITAN
  1. Home
  2. News
  3. PTGX

Protagonist Therapeutics, Inc - $PTGX STOCK NEWS

Welcome to our dedicated page for Protagonist Therapeutics news (Ticker: $PTGX), a resource for investors and traders seeking the latest updates and insights on Protagonist Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Protagonist Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Protagonist Therapeutics's position in the market.

News
Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event
Rhea-AI Summary

Protagonist Therapeutics, Inc. announced that their President and CEO, Dinesh V. Patel, Ph.D., will participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event in New York City on May 13-14, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update
Rhea-AI Summary

Protagonist Therapeutics reported strong financial results for Q1 2024 and significant corporate developments, including a partnership with Takeda for rusfertide, completion of Phase 3 trials for JNJ-2113, and upcoming milestones for the oral IL-17 program. The company's cash reserves remain healthy, with license and collaboration revenue of $255 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
Rhea-AI Summary
Protagonist Therapeutics, Inc. is progressing well with the Phase 3 VERIFY clinical trial evaluating rusfertide in polycythemia vera. The Company has randomized 241 patients and aims to reach the 250 patient enrollment target by March 2024. Top-line data for the 32-week primary endpoint is expected in the first quarter of 2025. Rusfertide shows promise in addressing unmet medical needs for PV patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
none
News
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda
Rhea-AI Summary
Protagonist Therapeutics, Inc. announces the closing of a collaboration and license agreement with Takeda for rusfertide, with a $300 million upfront payment expected in Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
none
-
News
Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year
Rhea-AI Summary
Protagonist Therapeutics, Inc. announced positive results from the Phase 2b FRONTIER 2 study evaluating JNJ-2113 for adult patients with moderate-to-severe plaque psoriasis. The study demonstrated sustained efficacy and similar safety results from Week 16 to Week 52, with high rates of skin clearance. The proportion of patients achieving PASI 75, 90, and 100 response rates at Week 16 were maintained through Week 52, confirming the durability of response. No evidence of dose-dependent increase in adverse events was observed across the treatment groups.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
none
-
News
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Protagonist Therapeutics, Inc. announces participation in three upcoming investor conferences in March 2024, including the 2024 Jefferies Biotech on the Bay Summit, 13th Annual Napa Valley Biotech Forum, and H.C. Wainwright 2nd Annual Autoimmune and Inflammatory Disease Virtual Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
conferences
News
Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Protagonist Therapeutics (PTGX) announces a collaboration agreement with Takeda Pharmaceuticals, receiving a $300 million upfront payment for rusfertide. The company extended its cash runway through Q4 2027. Significant clinical developments include the Phase 2b study results of JNJ-2113 and rusfertide published in the New England Journal of Medicine. Protagonist achieved $60 million in milestones related to JNJ-2113. Financially, the company reported cash, cash equivalents, and marketable securities of $341.6 million as of December 31, 2023, with license and collaboration revenue of $60 million for the fourth quarter and full year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.84%
Tags
earnings
-
News
New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera
Rhea-AI Summary
Protagonist Therapeutics, Inc. (PTGX) announced positive results from the REVIVE Phase 2 study evaluating rusfertide in polycythemia vera, a rare blood disorder. Rusfertide demonstrated efficacy in maintaining hematocrit levels below 45% without phlebotomy, reducing disease-related symptoms, and improving iron deficiency. The study met primary efficacy endpoints with high statistical significance. The Phase 3 VERIFY trial is ongoing, evaluating rusfertide's efficacy in uncontrolled hematocrit patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.4%
Tags
clinical trial
-
News
Protagonist Therapeutics Reports Granting of Inducement Awards
Rhea-AI Summary
Protagonist Therapeutics, Inc. (PTGX) issued inducement awards to Vice President Sid Reddy, granting him options to purchase 25,000 shares at an exercise price of $28.23. The shares vest over four years, with 25% vesting on the first anniversary of hire and the rest monthly over three years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
none
News
New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study
Rhea-AI Summary
Protagonist Therapeutics, Inc. announced the successful Phase 2b clinical trial of JNJ-2113 in adults with moderate-to-severe plaque psoriasis, achieving primary and secondary endpoints with PASI 100 and IGA 0 responses of 40.5 percent and 45.2 percent, respectively. The study showed a dose-ordered response in patients treated with JNJ-2113, with 79 percent of patients achieving a PASI-75 response at Week 16. The publication in the New England Journal of Medicine (NEJM) reflects the robust efficacy of JNJ-2113, currently being evaluated in multiple Phase 3 psoriasis studies in the ICONIC-program. The study also demonstrated improvements in patient-reported outcomes and a favorable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
clinical trial
Stock PTGX logo
Protagonist Therapeutics, Inc

Nasdaq:PTGX

PTGX Rankings

#2077 Ranked by Market Cap
#219 Ranked by Stock Gains
N/A Ranked by Dividends

PTGX Stock Data

1.59B
40.66M
1.71%
100.41%
5.9%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
NEWARK

About PTGX

protagonist therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs. protagonist's initial lead peptide product candidates, ptg-100 and ptg-200, are based on this approach, and the company believes these candidates have the potential to transform the existing treatment paradigm for inflammatory bowel disease (ibd), consisting primarily of ulcerative colitis and crohn's disease. ptg-100, a potential first-in-class oral peptide alpha-4-beta-7 integrin antagonist, is currently in a global phase 2b clinical trial for treatment of moderate-to-severe ulcerative colitis. ptg-200, a first-in-class oral interleukin-23 receptor antagonist